** Shares of biotech firm Oruka Therapeutics ORKA.O rise 2.83% to $70.90 premarket

** Co signs global collaboration with Halozyme HALO.O to develop psoriasis treatment using Hypercon technology

** Psoriasis is a chronic skin disease that causes red, scaly patches due to an overactive immune system

** Oruka to combine Hypercon with its lead experimental drug ORKA-001 to reduce dosing frequency, co says

** Technology enables smaller injection volumes, potentially improving convenience for patients - ORKA

** Deal includes upfront payment, milestone payouts and royalties for Halozyme, terms undisclosed - ORKA

** As of last close, stock up about two fold YTD